Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, talks about the impacts of the COVID-19 pandemic on the treatment of lung cancer, highlighting the importance of recovering diagnostic and treatment services, and the future role of screening and neoadjuvant and adjuvant immunotherapy. Dr Newsom-Davis also discusses the use of KRAS inhibitors, such as sotorasib, and antibody-drug conjugates. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
